The short version
- Why people research itFat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
- What the evidence isNo trials of this compound.
- What to watchBurning or numbness that spreads or persists.
How DADA works
The dichloroacetate moiety inhibits pyruvate dehydrogenase kinase (PDK), reactivating pyruvate dehydrogenase — pushing cells out of glycolysis back into mitochondrial glucose oxidation (reversing the Warburg shift); the diisopropylamine carrier adds a lipotropic/circulatory angle.
The active half of this compound is dichloroacetate, and it does one thing at one enzyme: it inhibits pyruvate dehydrogenase kinase. Pyruvate dehydrogenase is the gate between glycolysis and the mitochondrion — it converts pyruvate to acetyl-CoA, the step that commits a carbon skeleton to oxidation rather than to lactate.
Which makes this one of the very few compounds in the Vault whose mechanism is a single, named, well-characterized enzyme step. Most pages here have to reason about receptors with unknown occupancy. This one has a substrate, a product, and a phosphorylation site.
- Oral
- Injectable
On the goal map: Direct lipolysis & adrenergic drive (Lose fat)
Research on DADA6 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Human clinical evidence
No trials of this compound. Its active moiety, dichloroacetate, has real human data — decades of use in congenital lactic acidosis and mitochondrial disease, and small trials in glioblastoma and pulmonary hypertension.
No completed human trialWhich is the reason DCA has not progressed as a chronic therapy despite consistent mechanistic interest.
Correlative data
Very limited use, mostly in metabolic and oncology-adjacent research contexts. The DCA experience is the relevant real-world record.
How the mechanism reads
The dichloroacetate portion inhibits pyruvate dehydrogenase kinase, which releases the brake on pyruvate dehydrogenase — pushing pyruvate into the mitochondria for oxidation rather than into lactate.
MechanisticThis reverses the Warburg shift, the glycolytic metabolism cancer cells favor, and restoring mitochondrial oxidation restores their apoptotic sensitivity. That is the oncology rationale and it is mechanistically sound.
MechanisticThe neuropathy is mechanism-linked, not incidental — peripheral nerves are sensitive to the metabolic shift, and it is the predictable cost of forcing substrate flux in every tissue at once.
Mechanistic
Sources
- James MO, et al. Therapeutic applications of dichloroacetate and the role of glutathione transferase zeta-1. Pharmacology and Therapeutics 2017 · PMID 27771434
- Stacpoole PW. The dichloroacetate dilemma: environmental hazard versus therapeutic goldmine--both or neither?. Environmental Health Perspectives 2011 · PMID 20920954
- Koltai T. Dichloroacetate for Cancer Treatment: Some Facts and Many Doubts. Pharmaceuticals (Basel) 2024 · PMID 38931411
- Wei M, et al. The antitumor effect of diisopropylamine dichloroacetate on non-small cell lung cancer and its influence on the tumor immune microenvironment. Frontiers in Oncology 2024 · PMID 39267851
- Bi M, et al. DADA Enhances CD8+ T Cell Stemness to Improve Anti-Tumor Immunity and Immunotherapy Efficacy. Advanced Science 2026 · PMID 41758776
- Savic D, et al. Hyperpolarized magnetic resonance shows that the anti-ischemic drug meldonium leads to increased flux through pyruvate dehydrogenase in vivo resulting in improved post-ischemic function in the diabetic heart. NMR in Biomedicine 2021 · PMID 33458907
DADA safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Existing peripheral neuropathy, including diabetic neuropathy, because nerve toxicity is dose-limiting.
- Thiamine deficiency or heavy alcohol use, which makes nerve damage more likely.
- Liver disease, since dichloroacetate is metabolized there and is a rodent liver carcinogen.
- Lactic acidosis or mitochondrial disease.
- Pregnancy, given dichloroacetate toxicity in animal embryos.
What’s expected
- Lactate falls as pyruvate dehydrogenase is reactivated.
- Tingling or numbness in hands and feet as the early nerve signal.
- A glycolysis-to-oxidation shift in tumor models.
Watch for
- Burning or numbness that spreads or persists.
- Unexplained weakness or unsteady walking.
- Dark tea-colored urine or pale stools with yellow skin.
Labs that tell you it’s working
- Vitamin B1 (Thiamine), Blood: low thiamine raises the risk of the neuropathy this compound causes.
- Comprehensive Metabolic Panel: liver enzymes and bicarbonate for acid-base shifts.
- HbA1c: glucose oxidation shifts can lower glucose.
Dichloroacetate inhibits PDK, reactivating PDH and reversing glycolytic bias; diisopropylamine carrier; cumulative peripheral neuropathy is the known toxicity. PMID 27771434 PMID 20920954
Bloodwork to runHow you would know it is working: 8 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
DADA FAQ4 common questions
- Is DADA approved for human use?
- No. DADA is a research compound. No completed randomized human trial has given it yet.
- What is DADA researched for?
- Fat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
- Which labs show whether it's doing anything?
- Vitamin B1; Comprehensive Metabolic Panel; HbA1c: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for DADA: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.



